MonTa Biosciences ApS: Financial statements 2017
CVR: 36697016
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
MonTa Biosciences ApS (CVR 36697016) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -24,932 and a net result of DKK -653,993. Equity in the 2017 report amounted to DKK 1,445,920. The solvency ratio was 97%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -24,932
- Profit/Loss
- DKK -653,993
- Equity
- DKK 1,445,920
- Total Assets
- DKK 1,490,929
- Employees
- 1
Official annual report
Keep an eye on MonTa Biosciences ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
MonTa Biosciences ApS has published its interim report for the period July 1, 2016 – December 31, 2016.
As of February 22, 2017, Thomas Lars Andresen has joined the board of directors of MonTa Biosciences ApS.
As of February 22, 2017, Esper Boel has joined the board of directors of MonTa Biosciences ApS.
As of February 22, 2017, Peter Birk Rasmussen has joined the board of directors of MonTa Biosciences ApS.
About MonTa Biosciences ApS
MonTa Biosciences ApS is a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MonTa Biosciences IVS. The management consists of Simon Skjøde Jensen. The board consists of Lone Schøtt Kunøe (chair), Esper Boel, Sven Madsen and Søren Tulstrup. The company's owners include Jonas Rosager Henriksen, TLA-HOLDING 2010 ApS and JENSEN BIOCONSULT ApS. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 1,811,082 and a net result of DKK -4,776,853 compared with DKK -3,920,572 the year before. Equity in the 2025 report amounted to DKK -10,304,549.